OVERVIEW The Vaccine & Gene Therapy Institute (VGTI) at Oregon Health & Science University (OHSU) invites applications for professional-track faculty positions at the Assistant, Associate and Full Professor levels.
The Vaccine & Gene Therapy Institute at Oregon Health & Science University invites applications for professional-track faculty positions at the Assistant, Associate and Full Professor levels.
Involvement in an interdisciplinary research or complimentary program in the field of infectious disease. The successful applicant is expected to establish a productive, collaborative, externally-funded research program.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Angiodema: Gene therapy blocks painful hereditary disorderA single dose of gene therapy was enough to stop the painful swelling attacks caused by angiodema.
Read more »
Gene Therapy’s Promise Meets Nigeria’s Sickle Cell RealityThe U.S. FDA approved a breakthrough treatment for sickle cell anemia. But in Nigeria, social changes could make a bigger difference.
Read more »
With a nudge from Newsom, a new bill aims to legalize psychedelic-assisted therapy in CaliforniaAfter a failed attempt to decriminalize a short list of psychedelics last year, state Sen. Scott Wiener (D-San Francisco) is reintroducing legislation to make California the third state to legalize psychedelic-assisted therapy for adults.
Read more »
Gene therapy at CHOP allowed a deaf boy to hear. But some deaf people object to the treatment.A second deaf patient is undergoing the treatment, produced by Eli Lilly, at CHOP on Friday.
Read more »
First-Ever CRISPR-Based Therapy Approved for Sickle Cell DiseaseU.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
Read more »
Reward Offered for Information on Deaths of Endangered Gray Wolves in OregonA federal agency is offering a $50,000 reward for information about the deaths of three endangered gray wolves from the same pack in southern Oregon.
Read more »